Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
In humans the superior safety profile of
2022-10-26

In humans, the superior safety profile of lipid-associated formulations is characterized by decreased acute infusion-related reactions and dose-related nephrotoxicity, allowing the administration of larger doses and therefore similar efficacy with fewer administrations. In vitro studies and human cl
-
Regarding progression free survival analyzing clinical trial
2022-10-26

Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, p2016). Another Betaine of improvement of PFS only is that after antiangiogenic therapy glio
-
In a working group exposed
2022-10-25

In 2008, a working group exposed 12-month-old transgenic mice (mutation for human amyloid precursor protein expression) and their non-transgenic littermates to isoflurane and halothane for 120min per day for five days. It was concluded that in the transgenic mouse there was overload of amyloid prote
-
br Development of lorlatinib from crizotinib to a
2022-10-25

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
A selected set of these new
2022-10-25

A selected set of these new derivatives was then used for functional assays at the human A1AR showing, as expected, an antagonist profile with IC50 values at nanomolar level. The same molecules showed also to be efficacious as nanomolar antagonists in a functional assay aimed at analyzing their abil
-
The same applies also to
2022-10-25

The same applies also to intermediate , formally obtained by elimination of the R substituent from compound . If compared to the thienopyrimidine derivatives (series , C), the thieno[3,2-]pyridazin-5(4H)-ones – explored herein seem to maintain similar size and shape and also analogue structural char
-
We have previously reported that
2022-10-25

We have previously reported that interfering with Adaptaquin assembly dynamics by knocking down cofilin-1 in hMSCs increased polymerized actin that promoted osteoblast cell differentiation through a mechanism of enhancing focal adhesion kinase (FAK), p38 and c-Jun N-terminal kinase (JNK) signaling (
-
br Colorectal carcinoma The growth rate of murine colon aden
2022-10-25

Colorectal carcinoma The growth rate of murine colon adenocarcinoma tumors decreased upon inhibition of 5-LOX, an enzyme that harbors counteracting properties to 15-LOX [28]. It is not clear whether 15-LOX was associated with this phenomenon, but its expression is induced in the colon carcinoma c
-
Apoptosis signal regulating kinase ASK also referred to as
2022-10-25

Apoptosis signal-regulating kinase 1 (ASK1, also referred to as MAP3K5)(Ichijo et al., 1997) participates in many different stress responses, including apoptosis (Chang et al., 1998, Chen et al., 1999, Ichijo et al., 1997, Kanamoto et al., 2000, Noguchi et al., 2008, Saitoh et al., 1998, Tobiume et
-
br Material and methods br
2022-10-25

Material and methods Results Discussion This study explores the hypothesis that ASK1, via transcriptional upregulation by E2F1, molecularly defines AT that supports a dys-metabolic obese phenotype in humans. We demonstrate associations between increased visceral-AT ASK1 expression and multi
-
br Experimental and simulation section br Acknowledgments Fi
2022-10-25

Experimental and simulation section Acknowledgments Financial support for this work was provided by the National Natural Science Foundation of China (No. 81101688). We would like to thank NC State University High Performance Computing Center for providing us computing resources, and Dr. Lihui
-
The sequential behavioral approach used in the present
2022-10-25

The sequential behavioral approach used in the present study reinforced the involvement of the BDNF/TRKB system in the effect of losartan. In mice with dampened BDNF expression, losartan was no longer able to exert antidepressant-like effects. Similar to what was observed after losartan treatment, t
-
Hesperadin br Hypothesis The hypothesis is that AhR in
2022-10-24

Hypothesis The hypothesis is that AhR in skin diseases could be an objective of study for future dermatological therapies. Both stimulation and inhibition of the receptor might have significant influences on neoplastic or inflammatory skin diseases. However, at present the functions of AhR are un
-
br ABCA modulates intracellular sphingolipid metabolism in t
2022-10-24

ABCA2 modulates intracellular sphingolipid metabolism in the LE/LY Recycling of plasma membrane lipids that occurs by constitutive endocytosis and vesicularization of complex glycolipids, complex sphingolipids and cholesterol as well as free cholesterol liberated from LDL after receptor-mediated
-
It has been reported that HT
2022-10-24

It has been reported that 5-HT2R involves in type 2 diabetes mellitus and 5-HT-induced IR [22,23]. The present study also demonstrated that it is 5-HT2R rather than other 5-HT receptors, including 5-HT1BR and 5-HT7R, in the liver that mediates HFD-induced abnormality of hepatic lipid metabolism, and
16003 records 388/1067 page Previous Next First page 上5页 386387388389390 下5页 Last page